BiotechTube
Amicoat

Amicoat

Oslo, Norway· Est.
amicoat.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Amicoat is a private, preclinical-stage biotech company pioneering antimicrobial peptide (AMP) coatings for medical devices to combat healthcare-associated infections (HAIs) and antimicrobial resistance (AMR). Its core asset is voxvoganan, a proprietary AMP effective against over 250 microbes, including antibiotic-resistant strains. The company operates a B2B partnership model, supporting device manufacturers in integrating its technology, and is backed by notable Norwegian investors like Kistefos AS.

Infectious DiseaseHealthcare-Associated Infections

Technology Platform

Patented antimicrobial peptide (AMP) platform featuring voxvoganan, a unique AMP effective against 250+ microbes. Technology focuses on coating and integrating the peptide into medical device materials for localized, sustained antimicrobial effect.

Opportunities

The global crisis of antimicrobial resistance (AMR) and high rates of healthcare-associated infections (HAIs) create a massive, urgent need for innovative prevention technologies.
Amicoat's nature-inspired, broad-spectrum peptide technology aligns with the trend towards sustainable and non-antibiotic solutions, potentially allowing it to capture significant market share in the antimicrobial coatings segment for medical devices.

Risk Factors

Key risks include the need to prove long-term safety and efficacy of its peptide coating in human clinical use through partners' trials, navigating complex regulatory pathways for combination products, and intense competition from established and novel antimicrobial technologies.
Commercial success is entirely dependent on securing and supporting device manufacturer partners.

Competitive Landscape

Amicoat competes in the antimicrobial medical device coatings market against established technologies using silver, chlorhexidine, and antibiotic coatings. It also faces competition from other companies developing antimicrobial peptide (AMP) and non-antibiotic solutions. Differentiation hinges on voxvoganan's purported broad-spectrum efficacy, including against resistant strains, and its natural origin.

More companies in Small Molecule Drugs →More companies in Norway →